Unfortunately, your interpretations are wrong, and worse: not understanding basic underwriting is apparent. With regard to Common stock being reserved at TA as unrestricted to satisfy the obligations of any issued preferred stock: Lenders will want the brass tax they were promised and they want it in its ultimate issued form(the only form exchangeable back to cash): common stock.
Lets break it down a bit. Those prefered shares are only convertible to common stock. As stated by company, everywhere, repeatedly. So those shares currently issued to Auctus, even tho preferred, clearly need to have common stock reserved, as unrestricted, for the moment that conversion of preferred can take place. Every lender reserves the shares owed to them. For many reasons. Mostly to insure the shares promised are there and unrestricted. As the restrictions are on the conversion of preferred, not the common shares reserved themselves. Common Shares ready and reserved by TA(added to OS) to be drawn down on incrementally., not exceeding 5% ownership(repeated myself for clarity)
This is Undeniable. It is the common stock that is reserved unrestricted and accounted for at the TA in the companies OS count to date. The lender guaranteed for themselves that the common shares promised by the deal, are actually available and reserved. This is standard practice folks. Both by TA and a Lender. 100% standard.
Its okay. Keep racking the brain on where the exact number of common stock being questioned(same number as from Auctus prospectus) shares wise, is coming from(which is again from Auctus reserving the shares, like every lender, ever)
I wont continue to explain, or argue. Filings show all.
Knowledge is power folks. Dont be fooled folks. This comany is massively undervalued. Raised $23M in cash. No debt. Now active FDA approved clincal trials are starting. And ill help share that. Just as soon as i load all the $4 i can.
Glad at least to see the admitting of the incoming rush of liquidity with clinical trial updates. 100% agreed! And it appears they may be more to the advancement here. Worked with Pfizer already? Whoa?!? Winna Winna. Especially with $23M cash on the books and only a $30M Market Cap. Easy Button!
Market Data 
Markets 
AI
